Even after accounting for other factors like sex and hepatitis, higher visceral fat was still linked to higher ALT levels in HIV patients with high liver enzymes.

In HIV patients on placebo, losing visceral fat didn't lead to lower liver enzymes, unlike those taking tesamorelin.

In people with HIV and belly fat, higher amounts of visceral fat were linked to higher liver enzyme levels even when accounting for other factors like sex and hepatitis.

Whether HIV patients had hepatitis or not didn't change the link between losing visceral fat and improving liver enzyme levels.

In HIV patients with belly fat, higher amounts of visceral fat were linked to higher liver enzyme levels at the start of the study.

In people with HIV and belly fat, the amount of visceral fat didn't correlate with liver enzyme AST levels when other factors like sex and hepatitis were considered.